Nonlinear mixed effect models (NLMEM) with multiple responses are increasingly used in pharmacometrics, one of the main examples being the joint analysis of the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug. Efficient tools for design evaluation and optimisation in NLMEM are necessary. The R functions PFIM 1.2 and PFIMOPT 1.0 were proposed for these purposes, but accommodate only single response models. The methodology used is based on the Fisher information matrix, developed using a linearisation of the model. In this paper, we present an extended version, PFIM 3.0, dedicated to both design evaluation and optimisation for multiple response models, using a similar method as for single response models. In addition to handling multiple response models, several features have been integrated into PFIM 3.0 for model specification and optimisation. The extension includes a library of classical analytical pharmacokinetics models and allows the user to describe more complex models using differential equations. Regarding the optimisation algorithm, an alternative to the Simplex algorithm has been implemented, the Fedorov-Wynn algorithm to optimise more practical D-optimal design. Indeed, this algorithm optimises design among a set of sampling times specified by the user. This R function is freely available at www.pfim.biostat.fr. The efficiency of this approach and the simplicity of use of PFIM 3.0 are illustrated with a real example of the joint PKPD analysis of warfarin, an oral anticoagulant, with a model defined by ordinary differential equations.
Introduction
Nonlinear mixed effect models (NLMEMs) are increasingly used for the analysis of longitudinal data describing a biological process. They allow the estimation of the mean value of parameters in population studies and their inter-individual variability. They are also used for the joint modelling of several biological responses, such as the joint analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data [1] . Pharmacokinetics deals with the time-course of drug concentration, whereas pharmacodynamics refers to the time-course of drug action in the body. In pharmacometrics, analysis through a NLMEM is called the population approach. To estimate parameters in NLMEMs, maximum likelihood estimation is used primarily, although the likelihood for these models has no analytical solution. Specific algorithms, implemented in several software packages, have therefore been proposed to perform this maximisation [2] .
Before the estimation step, the investigator of a study is confronted with the choice of the design which is crucial for an efficient estimation of model parameters. A design in NLMEM, also called a population design, is composed of the number of elementary designs (or groups) and the specification of each elementary design and the associated number of subjects. In this setting, the term elementary design is used to describe a collection of subjects that have identical design characteristics defined by the number of sampling times and their allocation in time. To evaluate and compare population designs, a statistical approach based on the theory of optimum experimental design in classical nonlinear models and described for instance by Atkinson and Donev [3] or by Walter and Pronzato [4] has been extended to NLMEMs. This theory is based on the Fisher information matrix, whose inverse, according to the Cramer-Rao inequality, is the lower bound of the variance covariance matrix of any unbiased estimators of the parameters. Due to the lack of an analytical expression for the likelihood in NLMEM, an exact expression of the Fisher information matrix cannot be 4 defined. That is why an expression based on a linearisation of the model around the expectation of random effects has been proposed by Mentré et al. [5] and extended by Retout and Mentré [6] in the context of a single response model. The usefulness of this approach has been demonstrated, both by simulation [7, 8] and in real pharmacokinetic studies [9, 10] . To make the procedure more accessible to investigators, the approximate expression of the Fisher information matrix has been implemented in the R function PFIM 1.2, which can be used for design evaluation and comparison [11] .
Regarding optimisation, two approaches can be used, either the optimisation of exact designs or of statistical designs. In the case of optimisation of exact designs, the group structure of the design is fixed: the number of elementary designs, the number of samples per design and the number of subjects per elementary design are given and the design variables used to optimise are only the sampling times. Optimisation of statistical designs consists in optimising both the allocation of the sampling times and the whole group structure, that is to say the number of elementary designs, the number of samples per elementary designs and the proportion of subjects in each elementary design. An exact design is then derived by rounding off the proportion of subjects in each elementary design. Optimisation based on the Doptimality criterion has been implemented in the R function PFIMOPT 1.0 [12] , where the optimal design is the one that maximises the determinant of the Fisher information matrix. In PFIMOPT 1.0, both exact or statistical optimisation can be performed using the general Simplex algorithm [13] . It optimises the sampling times in given continuous intervals.
The main limitation of PFIM 1.2 and PFIMOPT 1.0 is that both aim at evaluating and optimising population designs only for single response models. Moreover, the model had to be written using an analytic expression and thus the need to use more complex models is limited. Regarding optimisation, the Simplex algorithm is a general optimisation algorithm.
However, even if its applicability has been shown in pharmacokinetic examples [8] , when 5 there are a large number of parameters to optimise, or when the model is complex, it could have difficulties in converging towards the optimal design and should sometimes be run again using the optimised design as a new initial design.
Recently, the expression for the Fisher information matrix has been extended in the context of a joint estimation of a set of parameters from multiple responses using the same linearisation as for single response [14] [15] [16] . In that context, some parameters can be included in several responses, as for instance in a classical PKPD model with the PD response depending on the PK parameters That joined estimation is then more informative, obtaining information on the PK parameters from both PK and PD responses. However, it increases the complexity of the computation of the Fisher information matrix compared to its computation for each response (single response). The relevance of the use of this approximation of the Fisher information matrix for that multiple response NLMEM context has been shown by Bazzoli et al. [14] through simulation of a PKPD model; results were very similar to those obtained from a more exact computation of the information matrix, without any linearization, using stochastic approximation through the SAEM algorithm of MONOLIX [17] .
This expression has been implemented in PFIM 3.0, an extension of PFIM to handle both design evaluation and optimisation in NLMEMs with multiple responses. The extension includes a library of classical analytical pharmacokinetics models and allows more complex models to be described using a system of differential equations. Regarding the optimisation step, an alternative to the Simplex has been added in PFIM 3.0, the Fedorov-Wynn algorithm.
It is a specific design optimisation algorithm implemented in PFIM 3.0 for statistical optimisation [5, 18] which has the property of converging towards the D-optimal design. The aim of this paper is to present PFIM 3.0. In section 2, we present a nonlinear mixed effect multiple response design and model and the expression of the population Fisher information matrix for multiple responses. Then, the structure of PFIM 3.0 and the description 6 of its features and use are presented in Section 3. Lastly, an example of the use of PFIM 3.0 to design a new trial for the joint analysis of the pharmacokinetics and pharmacodynamics of warfarin, an oral anticoagulant, is provided in Section 4.
Statistical methods

a. Nonlinear mixed effect multiple response design and model
A design for NLMEM, i.e. a population design, is composed of N individuals to whom we allocate an "elementary" design i ξ , 1, , = ! i N . Each elementary design is defined by a number i n of sampling times and their allocation in time. A population design is therefore described by N elementary designs :
leading to a total number n of observations.
In the case of a multiple response model, an elementary design for one individual i is composed of several sub-designs, i.e ( ) , , ,
where ik y , 1, , k K = ! , is the vector of observations for the k th response. Each of these responses is associated with a known function f k which defines the nonlinear structural model. The K functions f k can be grouped in a vector of multiple response models F, such as: diagonal Ω matrix with no correlation between the random effects.
The statistical model is thus given by:
where i ε is the vector composed of the K vectors of residual errors ik ε , 1, , k K = ! , associated with the K responses. We also suppose ik Let Ȍ be the vector of population parameters to be estimated, i.e. b. Fisher information matrix
The population Fisher information matrix
for multiple response models with the population design Ξ Ξ Ξ Ξ is given by:
Y is the log-likelihood of the vector of the whole observations Y for the population parameters Ȍ.
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Therefore, taking the second derivatives, the population Fisher information matrix for N individuals can also be defined as the sum of the N elementary information matrices
In the case of a limited number Q of groups, it is expressed as:
The expression of an elementary Fisher information matrix for multiple responses has been described in Bazzoli et al. [14] where further details are given. For the sake of simplicity, we have omitted the index i for the individual in the following. The Fisher information matrix is a block matrix depending on the approximated marginal expectation E and variance V of the observations. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 Note that in this work, we consider that the variance of the observations with respect to the mean parameters is constant, i.e. ( , ) 0
3. Implementation of PFIM 3.0 using R software 
a. Model specification
In PFIM 3.0, the model has to be entered in a model file called by default model.r. It must be specified by the user either in its analytical form or by using a system of differential equations. This extension to a system of differential equations requires the use of the lsoda function included in the library "odesolve" implemented by Setzer to solve the system [20] and the fdHess function included in the library "nlme" developed by Pinheiro and Bates [21] for numerical derivatives. The lsoda function uses a function of the same name written in Fortran by Petzold and Hindmarsh [22, 23] . This function solves a system of differential 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 equations using the Adams method, a predictor-corrector method for non-stiff systems; it uses the BDF (Backward Differentiation Formula) for stiff systems. Regarding the function fdHess, it evaluates an approximate gradient of a scalar function using finite differences.
Moreover, a library of standard PK models has been added. Twelve PK models are included: one or two compartment models, with first order oral, bolus or infusion administration and after a single dose, multiple doses or steady-state. Only models with first order elimination are presently available in the library of PFIM 3.0. Currently, there are no models with lag time. A list of the models and their characteristics included in the library is given in Table 1 .
b. Optimisation algorithms
An alternative to the Simplex algorithm has been added in PFIM 3.0, the Fedorov-Wynn algorithm. It is specifically dedicated to design optimisation problems and has the property of convergence towards the D-optimal design [5, 24, 25] . It optimises statistical designs (i.e the group structure, the number of samples per subject and the sampling times) for a given total number of samples. Minimum and maximum number of samples per subject are specified. To optimise the design, it considers only a set of possible sampling times defined by the user.
This can be an advantage in clinical practice to avoid unfeasible sampling times. Design optimisation can be constrained to the same sampling times across responses or not. It is also possible to give each elementary design sampling times from a different set of finite sampling times. For instance, it is possible to specify that each elementary design should include two points among a first set of sampling times (for instance Day 1) and a third point among a second set of sampling times (for instance Day 2). The user therefore specifies a list of sampling windows, and for each window, the set of possible sampling times and the miminum and maximum number of sampling times within that window. The Fedorov -Wynn algorithm  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   12 is programmed in C code and is linked to PFIM 3.0 through a dynamic library. Moreover, PFIM 3.0 uses the function combn in the R package "combinat" to generate all possible elementary designs from the set of pre-specified sampling times. To start the algorithm, an initial population design is required. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
Illustration of design for PKPD of warfarin
We aim to illustrate the use of PFIM 3.0 for the joint PKPD modelling of the time course of total racemic warfarin plasma concentrations and effect on prothrombin complex activity (PCA), by designing a new trial for this joint population analysis.
To do this, we use an example extracted from a classical pharmacology study published 40 years ago, by O'Reilly et al. [26, 27] on the pharmacokinetics and pharmacodynamics of 3 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   14 warfarin. Previously, these data have been fitted by Holford for the analysis of the dose-effect relationship of warfarin [28] using nonlinear mixed effects models. This example was presented in [29] but using different constraints in the optimisation step.
a. Population design and model
Warfarin is administered by a single oral dose of 100 mg. A one compartment model with first order absorption and elimination adequately describes the concentration data (PK). The PCA effect is described by a turnover model with inhibition of the input (PD). The model can be written as a system of ordinary differential equations:
where f PK and f PD are respectively the warfarin plasma concentrations and effect model and Values of the parameters are those obtained by Holford performing the simultaneous PKPD population analysis of warfarin. The population parameters were estimated by maximum likelihood, with the NONMEM software [30] . They are given in Table 2 .
b. Design optimisation for a new study
Using PFIM3.0, we first evaluate the design used in the previous study to determine the joint population PKPD model. We call this design the "empirical design" denoted emp Ξ . It involves one group of 32 healthy volunteers, with 13 sampling times at 0. This optimisation step is performed on the same number of 32 volunteers and the set of admissible sampling times is the set of times used in the empirical design except times 1 and 3 for PK. We then optimise a population design _ opt diff Ξ , with four sampling times per elementary design, but now, the optimal sampling times can be different for each response.
c. Results  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Fig. 3 and Fig. 4 , respectively. The optimal designs with their associated criterion are reported in Table 3 (Table 3 ). These two designs include a sample at 144 hours for the PK measurement whereas this sample is not present in the empirical design. Indeed, in population PK studies, when a proportional residual error is associated with the model, the optimal design includes the latest time among those proposed. In our case, for optimisation, we allowed the sample at 144 hours both for PK and PD responses.
In order to get an efficiency similar to that obtained with emp Ξ , we then derived two 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 17 standard error divided by the true value of the parameter, their total number of sampling times and the associated criterion are given in Table 4 . ω is increased compared to emp Ξ . The expected RSE on the terms for residual errors increase in both optimal designs, but they remain lower than 10%. For other parameters, the results from design optimisation, in terms of precision of estimation, are very close to those obtained with the empirical design, although "enlarged" designs involve only 440 and 416 measurements, respectively, 35% and 38% fewer than the empirical design. This sample reduction, together with a similar efficiency, leads to a more ethical and less costly study. Using PFIM 3.0, we find new efficient designs to study the joint PKPD of warfarin fitting to different clinical constraints.
Discussion
In this paper, we consider the R function PFIM 3.0, an extension of the R functions PFIM Mentré et al. [5] and extended for multiple responses [14] [15] [16] . In addition to handling multiple response models, several features have been integrated in PFIM 3.0. First, regarding the model specification, it can now be specified as a system of differential equations; this is an alternative to analytical model specification, particularly useful for complex models. For  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 "classical" pharmacokinetic models, a library of twelve pharmacokinetic models is available.
Concerning the optimisation algorithm, the Fedorov-Wynn algorithm has been added as an alternative to the general Simplex algorithm to optimise more practical D-optimal designs [24, 25] . Indeed, this algorithm allows design optimisation with fixed sampling times specified by the user which can be a great advantage with respect to medical constraints. This algorithm optimises the sampling times, which can be different or imposed to be identical across responses, but also optimises the group structure, using the approach of statistical designs. In addition to convergence issues using the Simplex algorithm compared to the Fedorov-Wynn [18] , optimisation within continuous intervals of times can be more questionable: the Simplex algorithm can, sometimes for a long time, pursue the optimisation by exchanging at each iteration one or several sampling times by some others which differ from the previous by only few seconds. This greatly slows down the whole optimisation process and has no relevance in clinical practice.
We illustrate the different options of this new extension of PFIM using a real example of the simultaneous population analysis of the time course of warfarin concentration and its effect on the prothrombin complex activity after single dose administration. We optimise and derive two population designs using the Fedorov-Wynn algorithm, either imposing the same sampling times across responses or not, and we compare them to an "empirical design" used in the previous study of warfarin [26, 27] . Globally, the expected precision of estimations are in the same range for the three designs, even if the number of samples per patient, and thus, the total number of samples are considerably reduced (38% fewer samples in the optimised designs compare to the empirical one). In this example, we show the interest of the optimisation procedure implemented in PFIM 3.0 from a medical, economic as well as ethical point of view. This approach can also be used for other complex modelling, such as the pharmacokinetics of a parent drug and its metabolite [31] . However, in some situations, due to 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   19 the different time scales of the pharmacokinetic profiles between the parent drug and the metabolite, different sampling times for the two responses may be required. It should be noted however, using the Fedorov-Wynn algorithm under this assumption, the number of possible elementary designs will be large and can considerably increase the computation time and the memory requirement. Limiting the number of allowed sampling times for each sampling window also helps to avoid computational issues.
In the example, the prothrombin complex activity is controlled by the rate of input R in and the output rate constant k out of the response, and the initial condition is given by the ratio of these parameters in out R k . It would be possible by using a modification of the parameterisation of the model to estimate the initial condition and R in or k out or even to fix the initial condition (for instance to 100%) and to estimate only R in or k out .
The present development of the Fisher information matrix for multiple response models takes into account all the population parameters to be estimated. Another approach would have been to optimise separately one design for the PK parameters and one for the PD parameters, fixing the PK parameters to their mean in the population (sequential approach).
However, this approach can be sub-optimal as no variability on the PK parameters is taken into account in the PD model. For instance, we compared this sequential approach to the one used in this paper, using the same example and similar constraints. We obtained the same optimal design for the PK model. Regarding the conditional D-optimal design for the PD, the design is quite different from Following the first theoretical work on optimal design for NLMEM, this research theme has grown rapidly both in methodological and application developments. An email mailing 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 20 list server PopDesign is now available for questions and comments about the experimental design of any study for which nonlinear mixed effect modelling is proposed for the analysis.
Since the first tool PFIM [11] , there are now several different software tools that implement an evaluation of the Fisher information matrix for population PK and PD models and propose optimisation of the experimental designs (PFIM, PopDes, PopED, WinPOPT) [32] . All software packages have ongoing development and have specific features according to the needs and goals of the research teams that developed them. PFIM is the only one using the R software. PFIM 3.0 uses an approximate Fisher information matrix to evaluate and optimise design.
This approximation, using a linearisation of the model, may be a limitation. Indeed, even if the relevance of this approximation has been shown by comparison to an exact Fisher information matrix using a simulation study, the PKPD model used was very simple [14] and may not be generalised to any complexity of the models. On the other hand, use of more exact methods can be computationally intensive and thus time consuming. Their need is thus questionable for nonlinear models for which design evaluation and optimisation require some a priori values of the parameters to be estimated, which are often not known precisely.
In parallel to PFIM 3.0, PFIM Interface 2.1, a graphical user interface version of PFIM 1.2 and PFIMOPT 1.0 has been recently proposed, allowing both design evaluation and optimisation but only for single response models. PFIM Interface 2.1 has the same features for model specification and optimisation algorithm as in PFIM 3.0. PFIM Interface will soon be extended to accommodate multiple response models.
In addition to the new features added in PFIM 3.0, several other extensions are planned.
First, the current library includes only pharmacokinetic models. Extensions to the usual pharmacokinetic-pharmacodynamic models are planned, even if model specification for 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 21 multiple responses is quite simple for the user as shown in the illustration using a system of differential equations.
Then, the next version could integrate the computation of the Fisher matrix for a nondiagonal variance of the random effects, as, in practice, one may want to allow correlation between the random effects. Expression of the Fisher information matrix has been proposed in this case for single response in Mentré et al. [5] and for multiple responses in Ogungbenro et al. [33] but has not been yet implemented in PFIM 3.0.
Afterwards, an extension of PFIM is envisaged to implement the expression of the Fisher information matrix for models including fixed effects for the influence of covariates on the parameters [6] , and thus, to compute the predicted power of the Wald test to detect a covariate effect as well as the number of subjects needed to achieve a given power [18] .
Moreover, Retout et al. [12] have recently used a modified version of PFIM for the problem of design optimisation using cost functions. They focus on the relative feasibility of the optimised designs, in terms of sampling times and of numbers of subjects. To do that the France.  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   22 PFIM functions, including their extensive documentation and examples to use them, are freely available from the PFIM website: http:/www.pfim.biostat.fr .  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   23  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 27 
Legends for Figures:
